Trial Profile

Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double blind, placebo-controlled trial.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Mar 2016 Results of post hoc analyses from this and other trial, presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
30 Aug 2013 The US FDA has approved the addition of data from this study in the prescribing information for flunisolide, according to a Meda media release.
11 Oct 2011 Results published in the Annals of Allergy, Asthma & Immunology, according to an Acton Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com